|Chemical and physical data|
|Molar mass||358.486 g·mol−1|
|3D model (JSmol)|
ADB-HEXINACA (also known as ADB-HINACA and ADMB-HEXINACA) is a cannabinoid designer drug that has been found as an ingredient in some synthetic cannabis products, first appearing in early 2021. It is a longer chain homologue of previously encountered synthetic cannabinoid compounds such as ADB-BUTINACA and ADB-PINACA.
- ^ Kronstrand R, Norman C, Vikingsson S, Biemans A, Valencia Crespo B, Edwards D, et al. (November 2021). "The metabolism of the synthetic cannabinoids ADB-BUTINACA and ADB-4en-PINACA and their detection in forensic toxicology casework and infused papers seized in prisons". Drug Testing and Analysis. 14 (4): 634–652. doi:10.1002/dta.3203. PMID 34811926. S2CID 244490343.
- ^ Gilbert N, Costello A, Ellison JR, Khan U, Knight M, Linnell MJ, et al. (December 2021). "Synthesis, characterisation, detection and quantification of a novel hexyl-substituted synthetic cannabinoid receptor agonist: (S)-N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-hexyl-1H-indazole-3-carboxamide (ADB-HINACA)" (PDF). Forensic Chemistry. 26: 100354. doi:10.1016/j.forc.2021.100354.